| 2025 | Germline BRCA1/2 Mutation Prevalence in Unselected ER-Low/HER2-Negative Breast Cancer | ANNALS OF SURGICAL ONCOLOGY |
| 2025 | Decision-Making Patterns for Clinically Node-Positive, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: Insights From a Survey of Breast Cancer Experts | JOURNAL OF BREAST CANCER |
| 2025 | Body mass index and progesterone receptor in postmenopausal ER-positive/HER2-negative breast cancer: A nation-wide study in Korean breast cancer society and the multi-institutional cohort | BREAST |
| 2025 | Clinical relevance of clinical treatment score post-5 years (CTS5) in HR-positive, HER2-positive breast cancer
| NPJ BREAST CANCER |
| 2025 | Additional prognostic value of the BCT score in ER+HER2-breast cancer patients receiving a 21-gene assay-guided adjuvant treatments
| FRONTIERS IN ONCOLOGY |
| 2025 | Pathological complete response, histologic grade, and level of stromal tumor-infiltrating lymphocytes in ER + HER2- breast cancer
| BREAST CANCER RESEARCH |
| 2025 | Adjuvant Trastuzumab Plus Pertuzumab Versus Trastuzumab Alone in Patients Achieving Pathologic Complete Response After Chemotherapy With Trastuzumab and Pertuzumab: A Retrospective Cohort Study
| CLINICAL BREAST CANCER |
| 2024 | Stromal tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single-center real-world study
| BREAST CANCER RESEARCH |
| 2024 | Clinical Relevance of TP53 Mutation and Its Characteristics in Breast Cancer with Long-Term Follow-Up Date
| CANCERS |
| 2024 | Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 h+HER2-breast cancer: a retrospective analysis
| BREAST CANCER RESEARCH |
| 2024 | Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates
| BREAST CANCER RESEARCH |
| 2024 | Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade
| CANCERS |
| 2023 | Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer
| JAMA NETWORK OPEN |
| 2023 | Optimal treatment strategy for hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer patients with 1-2 suspicious axillary lymph node metastases on breast magnetic resonance imaging: upfront surgery vs. neoadjuvant chemotherapy
| FRONTIERS IN ONCOLOGY |
| 2023 | Resolution of Nonmass Enhancement Extension to the Nipple at Breast MRI after Neoadjuvant Chemotherapy: Pathologic Response and Feasibility for Nipple-sparing Mastectomy | RADIOLOGY |
